You just read:

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

News provided by

TapImmune Inc.

Feb 03, 2016, 08:30 ET